Evaluating the Long-Term Cost-Effectiveness of Liraglutide 1.2 Mg and Exenatide in Patients with Type 2 Diabetes Mellitus.

L. W. Shi,S. Han,F. Liu

DOI: https://doi.org/10.1016/j.jval.2014.08.161

IF: 5.156

2014-01-01

Value in Health

Abstract:To evaluate the long-term economic and health outcomes associated with once daily liraglutide 1.2 mg, the most frequently prescribed dosage in China, versus twice daily exenatide 10 μg prescribed according to National Institute for Health and Clinical Excellence recommendations in clinical practice in patients with Type 2 Diabetes Mellitus (T2DM). A published and validated computer simulation model (CORE Diabetes Model) was used to make the projection of 30-year long-term economic and health outcomes. Simulated cohorts and treatment effects were derived from results of a retrospective chart audit with a median follow-up of 48 weeks including 256 patients receiving liraglutide and 148 receiving exenatide. Treatment costs were derived from drug retail prices in Chinese market. The diabetes management and complication costs were obtained from Chinese published data. Projections were made from a societal perspective with an annual discounting rate of 3%. One-way sensitivity analyses were performed. Long term projections demonstrated that compared with exenatide, liraglutide 1.2 mg was associated with lower cumulative incidences of diabetes complications and improved long term health outcomes for patients with T2DM. Compared with exenatide, the cumulative incidences of eye disease, renal disease, stroke event, and myocardial infarction event with liraglutide were reduced by 1.657%, 1.45%, 0.639% and 1.392% respectively. Liraglutide 1.2mg was associated with improvements in life expectancy of 0.109 years and 0.092 quality-adjusted life years (QALYs) versus exenatide. The costs of complications were reduced by 1,769 CNY (111,567 vs 113,336), resulting in a total direct medical cost saving of 7,626 CNY. These results indicated that liraglutide 1.2 mg was cost saving approach in comparison with exenatide. Sensitivity analyses demonstrated the robustness of results. The treatment of liraglutide 1.2 mg improved patient health and economic outcomes versus exenatide, and was a dominant treatment approach for T2DM patients in clinical practice.